Michael Cullen

2.1k total citations
42 papers, 1.4k citations indexed

About

Michael Cullen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Michael Cullen has authored 42 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in Michael Cullen's work include Lung Cancer Treatments and Mutations (14 papers), Testicular diseases and treatments (13 papers) and Lung Cancer Research Studies (12 papers). Michael Cullen is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Testicular diseases and treatments (13 papers) and Lung Cancer Research Studies (12 papers). Michael Cullen collaborates with scholars based in United Kingdom, United States and France. Michael Cullen's co-authors include Michael A. Russell, Lucinda Billingham, Neil Steven, Claire Gaunt, Robert Huddart, Daniel Rea, Peter Simmonds, Sally Stenning, Simon Gollins and Mark Bower and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Cullen

42 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Cullen United Kingdom 18 964 487 248 226 210 42 1.4k
Lissandra Dal Lago Belgium 18 1.2k 1.2× 254 0.5× 305 1.2× 103 0.5× 108 0.5× 54 1.7k
Indrajit Fernando United Kingdom 15 702 0.7× 264 0.5× 109 0.4× 198 0.9× 150 0.7× 48 1.3k
Junshik Hong South Korea 25 685 0.7× 498 1.0× 325 1.3× 132 0.6× 466 2.2× 179 2.0k
Javier Hornedo Spain 19 747 0.8× 205 0.4× 150 0.6× 126 0.6× 68 0.3× 53 1.2k
Ji Yun Lee South Korea 24 708 0.7× 662 1.4× 437 1.8× 321 1.4× 160 0.8× 105 1.9k
I Hudson United Kingdom 19 697 0.7× 163 0.3× 669 2.7× 167 0.7× 99 0.5× 28 1.8k
Ki‐Seong Eom South Korea 25 614 0.6× 96 0.2× 427 1.7× 242 1.1× 162 0.8× 188 2.3k
Eli Muchtar United States 27 682 0.7× 140 0.3× 1.3k 5.4× 475 2.1× 303 1.4× 176 2.8k
E. J. Freireich United States 22 512 0.5× 172 0.4× 297 1.2× 92 0.4× 190 0.9× 66 1.6k
Ingo Schmidt‐Wolf Germany 20 2.7k 2.8× 717 1.5× 570 2.3× 1.1k 4.8× 216 1.0× 73 3.6k

Countries citing papers authored by Michael Cullen

Since Specialization
Citations

This map shows the geographic impact of Michael Cullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Cullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Cullen more than expected).

Fields of papers citing papers by Michael Cullen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Cullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Cullen. The network helps show where Michael Cullen may publish in the future.

Co-authorship network of co-authors of Michael Cullen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Cullen. A scholar is included among the top collaborators of Michael Cullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Cullen. Michael Cullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huddart, Robert, Rhian Gabe, Fay Cafferty, et al.. (2014). A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). European Urology. 67(3). 534–543. 20 indexed citations
2.
Ting, Yuk, Michael Cullen, & Syed A. Hussain. (2011). Biology of Germ Cell Tumors. Hematology/Oncology Clinics of North America. 25(3). 457–471. 4 indexed citations
3.
Warfield, Adrian, et al.. (2010). Small Cell Lung Cancer in a 26-Year-Old Man with Significant Cannabis Exposure. Journal of Thoracic Oncology. 6(1). 218–219. 10 indexed citations
4.
Hussain, Syed A., Yuk Ting, D. Palmer, Paul Hutton, & Michael Cullen. (2008). Biology of testicular germ cell tumors. Expert Review of Anticancer Therapy. 8(10). 1659–1673. 16 indexed citations
5.
Hussain, Syed A., Yuk Ting, & Michael Cullen. (2008). Management of metastatic germ cell tumors. Expert Review of Anticancer Therapy. 8(5). 771–784. 13 indexed citations
6.
Crinò, Lucio, Petr Zatloukal, Martin Reck, et al.. (2007). B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study. Journal of Thoracic Oncology. 2(8). S341–S341. 19 indexed citations
7.
Latz, Jane E., Susumu Adachi, James T. Symanowski, et al.. (2007). PD4-3-4: Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations. Journal of Thoracic Oncology. 2(8). S455–S456. 6 indexed citations
8.
9.
Pascoe, Jennifer & Michael Cullen. (2006). The prevention of febrile neutropenia. Current Opinion in Oncology. 18(4). 325–329. 8 indexed citations
10.
Williams, Sarah, et al.. (2006). Role of Prophylactic Antibiotics in the Prevention of Infections After Chemotherapy: A Literature Review. PubMed. 3(4). 207–216. 7 indexed citations
11.
Cullen, Michael, et al.. (2006). Antibiotic prophylaxis in chemotherapy‐induced neutropenia: time to reconsider. Hematological Oncology. 24(3). 120–125. 27 indexed citations
12.
Leibovici, Leonard, Mical Paul, Michael Cullen, et al.. (2006). Antibiotic prophylaxis in neutropenic patients. Cancer. 107(8). 1743–1751. 129 indexed citations
13.
Seiden, Michael V., Alan N. Gordon, Diane C. Bodurka, et al.. (2005). A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecologic Oncology. 101(1). 55–61. 23 indexed citations
14.
Cullen, Michael, Neil Steven, Lucinda Billingham, et al.. (2005). Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. New England Journal of Medicine. 353(10). 988–998. 275 indexed citations
15.
Cullen, Michael & Sally Stenning. (2004). Clinical trials with moving targets: a commentary on a non-inferiority trial in testicular cancer. The Lancet Oncology. 5(2). 129–132. 5 indexed citations
16.
Cullen, Michael. (2001). 'Best supportive care' has had its day. The Lancet Oncology. 2(3). 173–175. 22 indexed citations
17.
Allen, Simon, et al.. (1996). Phase II study of mitomycin, ifosfamide and cisplatin in adenocarcinoma of the oesophagus. Cancer Chemotherapy and Pharmacology. 37(5). 496–498. 8 indexed citations
18.
Cullen, Michael, et al.. (1996). Adjuvant therapy for stage I testicular cancer. Cancer Treatment Reviews. 22(4). 253–264. 9 indexed citations
19.
Cullen, Michael. (1995). Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Lung Cancer. 12. S95–S106. 11 indexed citations
20.
Russell, Michael A., et al.. (1992). P-glycoprotein possesses A 1,4-dihydropyridine-selective drug acceptor site which is alloserically coupled to a vinca-alkaloid-selective binding site. Biochemical and Biophysical Research Communications. 188(1). 440–445. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lissandra Dal Lago Breakdown of academic impact, for papers by Indrajit Fernando Breakdown of academic impact, for papers by Junshik Hong Breakdown of academic impact, for papers by Javier Hornedo Breakdown of academic impact, for papers by Ji Yun Lee Breakdown of academic impact, for papers by I Hudson Breakdown of academic impact, for papers by Ki‐Seong Eom Breakdown of academic impact, for papers by Eli Muchtar Breakdown of academic impact, for papers by E. J. Freireich Breakdown of academic impact, for papers by Ingo Schmidt‐Wolf
Rankless by CCL
2026